AskBio Inc — Biomedical Watch V2

Traitements9programmes

Essais3liés

Publications5liées

SourceDBlocale

Traitements

9

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
AAV2-GDNF gene therapyThe objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.	Parkinson	Phase 2	Thérapie génique	United States, Germany, Poland, United Kingdom	À vérifier
AB-1003 dose level 1The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)	Myopathies	Phase 1/2	À vérifier	United States	À vérifier
AB-1003 dose level 2The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)	Myopathies	Phase 1/2	À vérifier	United States	À vérifier
AB-1005This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring. Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI. Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT. Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery	Parkinson	Phase 2	À vérifier	United States	À vérifier
control surgeryThe objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.	Parkinson	Phase 2	À vérifier	United States, Germany, Poland, United Kingdom	À vérifier
Prescriptive Infusion AlgorithmThis study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring. Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI. Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT. Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery	Parkinson	Phase 2	À vérifier	United States	À vérifier
AB-1003 dose level 1The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)	Myopathies	Phase 1/2	À vérifier	United States	À vérifier
AAV2-GDNF gene therapyThe objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.	Parkinson	Phase 2	Thérapie génique	United States, Germany, Poland, United Kingdom	À vérifier
Prescriptive Infusion AlgorithmThis study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring. Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI. Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT. Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery	Parkinson	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
Prescriptive Infusion Algorithm	Parkinson	Phase 2	NCT07215403	Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)	NOT_YET_RECRUITING
AAV2-GDNF gene therapy	Parkinson	Phase 2	NCT06285643	A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)	ACTIVE_NOT_RECRUITING
AB-1003 dose level 1	Myopathies	Phase 1/2	NCT05230459	A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)	ACTIVE_NOT_RECRUITING

Publications

5

Molécule	Indication / population	Titre	Journal	Date
AB-1003 dose level 2		Assessment of Xiao'er Xiexieting Keli-induced toxicity in juvenile rats.	Journal of ethnopharmacology
AB-1003 dose level 1		In vivo antimalarial activity and acute toxicity of organic and aqueous leaf, stem and root extracts of Ajuga integrifolia Buch.-Ham. ex D. Don.	Journal of ethnopharmacology
AB-1003 dose level 2		Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta-analysis.	British journal of clinical pharmacology
AB-1003 dose level 1		Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study.	Journal of clinical medicine
AB-1003 dose level 1		Anticoagulation Stewardship in the Era of Practice-Changing Evidence: A Narrative Review of Recent Trials and Their Bedside Translation.	Journal of clinical medicine